Division of Infectious Diseases

Pharm To Exam Table – Candida glabrata Urinary Tract Infections

The following is a clinical review written by Allison Graner, UNMC College of Pharmacy PharmD candidate 2019, and supervised by Scott Bergman PharmD FIDSA, Clinical Pharmacy Coordinator of Nebraska Medicine Antimicrobial Stewardship Program What is the appropriate treatment for urinary tract infection caused by Candida glabrata? Infections caused by the fungus known as Candida, the most common fungus to be cultured in the microbiology lab… Continue Reading

Bacteriocidal versus Bacteriostatic: What Makes the Biggest Difference in VRE Bloodstream Infection?

An October 2018 publication in Critical Care Medicine by Chuang et al details a prospective study of adults in Taiwan, between 2010 -2015, aimed to assess all-cause mortality and rate of bloodstream clearance among patients with vancomycin-resistant enterococci (VRE) treated with daptomycin (bacteriocidal) versus linezolid(bacteriostatic). Patients were treated with conventional daptomycin (6 to < 9 mg/kg actual body weight), high-dose daptomycin(>9 mg/kg) or linezolid (600mg IV… Continue Reading

Pharm to Exam Table: Doravirine DRIVES the way to more ART options

The Department of Health and Human Services HIV guidelines panel currently recommends antiretroviral therapy (ART) consisting of two nucleoside reverse transcriptase inhibitors plus an integrase inhibitor for most treatment naïve HIV infected individuals1.  Prior to the advent of integrase inhibitors, the utilization of non-nucleoside reverse transcriptase inhibitor (NNRTI) based regimens had been common.   Both efavirenz and rilpivirine had been commonly used although both NNRTI’s present… Continue Reading

Are you a Pharmacist interested in an Infectious Diseases Clinical Practice? UNMC ID has the perfect job for you!

The Department of Pharmaceutical and Nutrition Care at Nebraska Medicine and the Division of Infectious Diseases at the University of Nebraska Medical Center (UNMC) are recruiting for a full-time clinical pharmacist to expand the Antimicrobial Stewardship Program and develop an Outpatient Parenteral Antimicrobial Therapy (OPAT) program in collaboration with a new Orthopedic Infectious Diseases service line. This is a unique position that allows a candidate… Continue Reading

Pharm To Exam Table: Dual Antiretroviral Therapy with Dolutegravir + Lamivudine

Pharm To Exam Table: Dual Antiretroviral Therapy with Dolutegravir + Lamivudine Currently, triple therapy regimens constituted with a two nucleoside reverse transcriptase inhibitor backbone and anchored by an integrase inhibitor has been the standard treatment for HIV infection. However, these conventional therapies are being challenged due to their long-term side effects. Dual therapy regimens were recently introduced with the first comprising of dolutegravir (DTG)/rilpivirine (RPV)…. Continue Reading

Pharm to Exam Table: Monoclonal Antibodies Make Their Way into HIV Treatment

Pharm to Exam Table: Clinical Pharmacology/Antimicrobial Updates – Trogarzo® (ibalizumab-uiyk), a new monoclonal antibody treatment approved for multi-drug resistant HIV-1  On March 6th 2018, the Food and Drug Administration approved a new monoclonal antibody called ibalizumab-uiyk, marketed under the tradename Trogarzo®. Ibalizumab-uiyk (IBA) is an intravenous treatment administered every two weeks. It is intended for use in combination with other antiretrovirals (in an optimized background regimen), for… Continue Reading

Pharm to Exam Table: Meet Biktarvy, the Newest of the Antiretroviral Family!

Pharm to Exam Table: Clinical Pharmacology/Antimicrobial Updates – Biktarvy, a new co-formulated integrase inhibitor-based treatment approved for HIV On February 7th 2018, the Food and Drug Administration approved a new combination antiretroviral drug called Biktarvy®(1). Biktarvy® (B/F/TAF) is a single-tablet, once daily regimen containing the novel integrase strand transfer inhibitor bictegravir coformulated with emtricitabine and tenofovir alafenamide (1). Current HIV guidelines recommend integrase strand transfer inhibitor… Continue Reading

Josh Havens, PharmD on “Why I Love ID”

Why I Love ID:  Infectious diseases, in general, is quite interesting, but I can really only speak from an HIV perspective. My initial career interests were not in infectious diseases and it was not until I threw myself into this niche world of HIV that I started to recognize a true affinity toward the field.  It is rare to find an infection that is such… Continue Reading

New Staff Spotlight – Danny Schroeder, PharmD

Tell us about the position you are starting:  I have recently started my role at Nebraska Medicine Bellevue as an Antimicrobial Stewardship pharmacist. I reach out to physicians at Nebraska Medicine Bellevue to discuss antibiotic therapy and try to obtain the best and safest therapy for our patients here. In addition, I work with Dr. Jasmine Marcelin in this role, she helps guide me with her… Continue Reading

Pharm to Exam Table – Trimethroprim/Sulfamethoxazole for Nocardiosis

Pharm to Exam Table: Clinical Pharmacology/Antibiotic Updates – Trimethroprim/Sulfamethoxazole for Nocardiosis Nocardia is an aerobic, gram-positive bacterium commonly found in soil, decomposing vegetation, fresh water, and salt water. Nocardia is typically considered an opportunistic pathogen, but there have been several cases of nocardiosis occurring in immunocompetent hosts. Patients that are most at risk of developing nocardiosis are those with malignancies, human immunodeficiency virus (HIV), solid-organ and hematopoietic stem cell… Continue Reading